Brought to you by 
InterMune, Roche form new danoprevir deal valued at $175mm
16 Nov 2022
Executive Summary
Four years after forming a global development and US co-promotion agreement with Roche for its hepatitis C protease inhibitor danoprevir, InterMune Inc. (respiratory and infectious disease therapeutics) has decided to cease its investment in the drug candidate, thereby terminating that 2006 deal. Roche now has sole ownership, holding worldwide development and commercialization rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
InterMune, Roche form new danoprevir deal valued at $175mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice